Posters1 — ASN Events

Posters1 — ASN Events

Posters1

Elucidating inflammatory meditated mechanisms of intrinsic and acquired chemo-resistance in non-small cell lung cancer (#171)

Anne-Marie Baird

Histopathology and genomics of tumours: a translational issue in biomedical science (#172)

Hematopoietic stem cell transplantation, survivorship and quality of life : Is it a small world after all? (#173)

Association of ABCA1 cholesterol transporter with poor outcome and aggressive phenotype in serous ovarian cancer. (#174)

Ellen L Hedditch

Determining the impact of additional public radiotherapy services on the public radiotherapy utilisation rate in Queensland (#175)

Comparative 2D and 3D Culture Studies as a Means to Identify Mechanisms of Chemo-Resistance (#176)

Anne-Marie Baird

Implementing a shared care model to prevent liver cancer and improve chronic hepatitis B outcomes in a high disease prevalence area. (#177)

TGFB-RELATED SIGNATURE OF EMT IDENTIFIES BASAL SUBTYPE OF BREAST CANCER (#178)

Predictive value of de novo and induced epithelial-mesenchymal transition in locally advanced breast cancer treated with neoadjuvant chemotherapy (#179)

Erik W Thompson

Final Report of a Phase I Trial of Lipovaxin-MM, a Novel Dendritic Cell-Targeted Liposomal Vaccine for Malignant Melanoma. (#180)

Evaluation of response from axitinib as per Choi criteria in previously treated patients with metastatic renal cell carcinoma (mRCC) (#181)

Utility of commonly available clinical parameters for predicting concurrent chemoradiotherapy toxicity following treatment of inoperable stage III non-small cell lung cancer. (#182)

Pembrolizumab for Metastatic Melanoma – One Year Results of Named Patient Access Program (#183)

Vladimir Andelkovic

Outcome of patients with stage III non-small cell lung cancer treated with neo adjuvant chemotherapy and radiotherapy in a tertiary care center (#184)

A review of skin outcomes for 100 patients treated with radiotherapy for skin cancer (SCC, BCC) and breast cancer at a local metropolitan hospital from 2011 – 2014 using a quantitative, non-experimental retrospective methodology. (#185)

PARAGON- An ANZGOG Phase 2 study of anastrazole in asymptomatic women with estrogen (ER)/ progesterone (PR) positive ovarian cancer with a CA125 progression after first line treatment. (#186)

Nivolumab (Nivo) monotherapy or in combination with ipilimumab (Ipi) for treatment of recurrent small cell lung cancer (SCLC) (#187)

Patient Medication Access Programs for the Treatment of Cancer. Patterns of Use and Patient Outcomes at a Tertiary Metropolitan Hospital (#188)

Christine V Carrington

Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): association of biomarkers with clinical outcomes (#189)

Treatment Outcome for Elderly Patients with Non small cell Lung Cancer (NSCLC) (#190)

Patient Adherence to Aromatase Inhibitor Treatment in Early Stage Breast Cancer – local experience from Western Sydney hospitals (#191)

Smoking and the influence of behavioural factors in the outcomes of patients with colon cancer (#192)

Rachel Delahunty

Impact of Chemotherapy-induced Alopecia on Cancer Patients in Regional Victoria (#194)

The experience of survival following Blood and Marrow Transplant in NSW, Australia. (#195)

Rare data for a common cancer: Survival Outcomes for Metastatic Breast Cancer (MBC) at Eastern Health, Victoria, Australia (#196)

Danielle A Ferraro

An update on the ANZMTG 01.07 WBRTMel trial – The role of Adjuvant whole brain radiotherapy for patients with melanoma brain metastases (#197)

Expanded cohort results from CheckMate 016: a Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC) (#199)

Longer-term follow-up of a phase 2 study (CheckMate 063) of nivolumab in patients with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC) (#200)

Safety and efficacy of nivolumab in an ongoing trial of a PD-L1^+/- patient population with metastatic non-small cell lung cancer (#201)

A PILOT STUDY TO ASSESS VALIDITY OF THE DASS-21SUBSCALES IN AN OUTPATIENT ONCOLOGY POPULATION (#202)

Claire E Johnson

Baseline predictors of early treatment failure in patients with Platinum Resistant/ Refractory (PRR) and Potentially Platinum Sensitive (PPS) recurrent ovarian cancer (ROC) receiving ≥3 lines of chemotherapy- The Gynaecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS) (#203)

Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067) (#204)

Safety and efficacy of microwave ablation in colorectal pulmonary metastases: 1-year follow-up (#205)

Subsequent line of therapy in metastatic NSCLC (mNSCLC): an indicator of success or failure? (#207)

Patterns of driver mutations in routine multigene diagnostic profiling in 1865 patients (#208)

Assessing the multidisciplinary lung cancer service: is best practice care evident? (#209)

Treatment Outcome for The Elderly Patients with Small Cell Lung Cancer (#210)

Shivanshan Pathmanathan

Identifying opioid medication error types, incidence and patient impact in adult oncology and palliative care settings: a systematic review. (#211)

Jane L Phillips

Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC) (#212)

Elizabeth R Plimack

Why adjuvant chemotherapy for stage III colon cancer was not given: reasons for non-recommendation by clinicians or patient refusal. (#213)

Khageshwor Pokharel

Phase 3, randomized trial (CheckMate 017) of nivolumab (Nivo) vs docetaxel in advanced squamous (SQ) cell non-small cell lung cancer (NSCLC) (#214)

Size matters: peripherally inserted central catheter (PICC) diameter and risk of upper-extremity thrombus in cancer patients – a pilot study. (#215)

Sensorineural Hearing Loss: Who is most at risk? (#216)

Exercising during neo-adjuvant chemoradiation therapy for rectal cancer patients: a feasibility study. (#217)

Supervised exercise during cancer treatment maintains or improves body composition and function. (#218)

‘Rethinking REAL-2: Real-life outcomes from an Australian retrospective audit of patients with metastatic oesophago-gastric adenocarcinoma (mOGC)’ (#219)

Claudia E.A Stretch

Implementation of Postoperative Nutritional Support for Gastric Cancer Patients in China (#221)

Quality of life and cytokine gene variation in breast, prostate, lung and brain cancer patients and their family caregivers (#222)

Kimberly Alexander

Sun Protection Practices of Undergraduate University Students (#223)

To assess the timeliness of access to treatment for patients with thoracic malignancies referred to MDM in the ACT Region (#224)

Madhawa De SIlva

Changing patterns of Pancreaticoduodenectomy surgery in Queensland (#225)

Are rare cancers killing our young people? (#226)

Suitable for chemotherapy? An analysis of an Australian geriatric oncology population (#227)

Harriet Herbison

Lenalidomide use in relapsed or refractory multiple myeloma patients at five large Queensland public hospitals. (#228)

Daniel McKavanagh

Temporal trends in the risk of developing multiple primary cancers: A systematic review (#229)

Evidence into practice: Dietetic and Speech Pathology Service for Gold Coast University Hospital Head and Neck cancer patients undergoing radiation therapy (#230)

Home-based Cancer Care: a Regional Perspective (#231)

ISCaHN Treatment Dashboard: Providing clinician decision support with data generated at the point of care. (#232)

Transversing the Silos (#233)

Diminishing disparities with an online blended-learning approach (#234)

Tips and tricks for the successful implementation of a learning management system (#235)

MANAGEMENT OF COMPLEX DISCHARGE PLANNING IN THE SETTING OF CANCER NURSING (#236)

An Innovative Interdisciplinary approach to Cancer Care Services “Removing the Band-Aid Effect”. Model of Care of Cancer Allied Health (#237)

Dawn Hutley
jacqueline Hampton

Lung Cancer Quality Improvement Study - Gold Coast University Hospital (#238)

Nutritional status, weight loss and associated characteristics of patients with oesophageal and gastro-oesophageal (GOJ) cancer: a descriptive study (#239)

Ka Hi (May) Mak

Is routine malnutrition screening needed at Liverpool Cancer Therapy Centre? (#240)

Ka Hi (May) Mak

“Self-reported satisfaction and outcomes based on referral source into Cancer Council WA Counselling Program” (#241)

A Quality Analysis on the Functionality of Multidisciplinary Teams (#242)

Implementing best practice approaches for the management of lung cancer: a national approach (#243)

Caroline Nehill

Shared follow-up care for early breast cancer (#244)

Caroline Nehill

Multidisciplinary approach to weight management in oncology patients- “Why weight?” (#245)

Convenient Chemotherapy– A New Paradigm for Pharmacy (#246)

Pre-screening for capacity to consent as a potential family bone marrow donor (#248)

Development and implementation of a multidisciplinary support program for carers of patients undergoing allogeneic haematopoietic stem cell transplantation (#249)

You Told Us, We Listened, We Acted: A Multidisciplinary Project Team Creating A More Therapeutic Cancer Care Environment By Partnering With Consumers (#250)

Are you ready to accept accountability? Improving patient safety and satisfaction in an acute oncology/haematology unit using a uniform clinical handover tool (#251)

From Sleepy Hollow to Survivorship Superstar: An example of Transformational Leadership in community cancer care (#252)

Merran Z Williams

Integrating Cancer Self Management Strategies (#253)

Parking at Victorian cancer treatment centers – issues and impacts (#254)

Implementation and evaluation of Lung Cancer Patient Seminar 2014 (#255)

Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice (#256)

Joel Cohen (Presenter on behalf of investigators)

Efficacy and reach of psychosocial interventions for improving cognitive functions in cancer survivors (#257)

Heather J Green

Evaluating patient information: Understanding Radiotherapy (#258)

Elizabeth Humphries

Unmet Needs of Asian and Caucasian Women with Breast Cancer: Findings from the Literature (#259)

Janelle Levesque

Oncology patients’ attitudes toward, and experiences with, somatic mutation tumour testing (#260)

Changing our ways: Developing an advanced practice role for dietitians (#261)

A REVIEW OF THE BLOOD TRANSFUSIONS IN CANCER PATIENTSTRASNFUSIONS (#262)

Padmini Thanayankezhil

The experiences and preferences of shared decision making and their associated factors among cancer patients undergoing radiation therapy (#263)

Self-guided psychological interventions for people with cancer: A systematic review (#264)

Why won’t patients with advanced cancer engage in ACP: Experience from an Australian ACP RCT (#265)

Martin Tattersall

A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours: The P3BEP Trial (ANZUP 1302) (#266)

Randomised phase 3 trial of the addition of Mitomycin to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer(ANZUP 1301) (#267)

Precision medicine for advanced pancreas cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) trial (#268)

Lorraine Chantrill

Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: the ANZUP ENZAMET Trial (ANZUP 1304) (#269)

Randomised phase 3 double-blind placebo-controlled trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasound-guided prostate biopsy (Pain-Free TRUS B): ANZUP 1501 (#270)

Rekindle Update: Rekindle is Demonstrating Broad Reach Across Australia in Providing Psychosexual Support to BOTH Cancer Survivors and Their Partners (#271)

Haryana Dhillon

OPAL: On-line and Phone Assistance for Lung cancer patients: A randomised controlled trial of on-line versus telephone-based information and support via Cancer Council services (#272)

Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer: ENZARAD (ANZUP 1303) (#273)

Scott G Williams